Categories: News

HTG Molecular Diagnostics to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

TUCSON, Ariz., Sept. 21, 2021 (GLOBE NEWSWIRE) — HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced that company management will present in a fireside chat in Cantor Fitzgerald’s Virtual Global Healthcare Conference, being held September 27th – 30th, 2021.

Details for the fireside chat are below:

Date: Thursday, September 30, 2021
Time: 2:00 PM Eastern / 11:00 AM Pacific
Webcast: https://wsw.com/webcast/cantor12/htgm/2086560

Management will also be available for 1×1 meetings. If you would like to request a meeting, please email corporateaccess@cantor.com

About HTG:
HTG is accelerating precision medicine from diagnosis to treatment by harnessing the power of transcriptnome-wide profiling to drive translational research, clinical diagnostics and targeted therapeutics across a variety of disease areas.

Building on more than a decade of pioneering innovation and partnerships with biopharma leaders and major academic institutes, HTG’s proprietary RNA platform technologies are designed to make the development of life science tools and diagnostics more effective and efficient and to unlock a differentiated and disruptive approach to transformative drug discovery. For more information visit www.htgmolecular.com.

Contact:

Ashley Robinson
Phone: (617) 430-7577
Email: arr@lifesciadvisors.com

Staff

Recent Posts

GE HealthCare drives innovation in theranostics with latest technological advances

GE HealthCare is helping advance clinical and operational excellence in theranostics and molecular imaging through…

22 hours ago

Saudi Arabia Concludes Landmark BIO 2025 Debut as Kingdom Opens Doors to Global Biotech Collaboration

From genomics to regulatory innovation, the Kingdom’s presence in Boston establishes it as a major…

22 hours ago

Enzon and Viskase Enter into Merger Agreement

Enzon and Viskase stockholders will respectively own approximately 15.9% and 84.1% of the combined companyCRANFORD,…

22 hours ago

Novo Nordisk’s subcutaneous and oral amycretin data published in The Lancet and presented at ADA 2025

Subcutaneous amycretin phase 1b/2a data on the safety, tolerability and weight loss potential in people…

22 hours ago